- Report
- October 2024
- 193 Pages
Global
From €3348EUR$3,545USD£2,849GBP
€3720EUR$3,939USD£3,166GBP
- Report
- September 2024
- 100 Pages
Global
From €5619EUR$5,950USD£4,782GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£3,014GBP
- Report
- April 2024
- 160 Pages
Global
From €4693EUR$4,969USD£3,993GBP
- Report
- December 2024
- 144 Pages
Global
From €14161EUR$14,995USD£12,051GBP
- Report
- September 2018
- 174 Pages
Global
From €1299EUR$1,375USD£1,105GBP
€2597EUR$2,750USD£2,210GBP
- Report
- March 2024
- 397 Pages
Global
From €7508EUR$7,950USD£6,389GBP
- Report
- August 2023
- 133 Pages
Global
From €7083EUR$7,500USD£6,027GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2597EUR$2,750USD£2,210GBP
- Report
- March 2024
- 200 Pages
Global
From €3919EUR$4,150USD£3,335GBP
- Report
- December 2023
- 117 Pages
Global
From €14161EUR$14,995USD£12,051GBP
- Drug Pipelines
- September 2022
- 129 Pages
Global
From €14161EUR$14,995USD£12,051GBP
- Report
- March 2021
- 120 Pages
Global
From €14161EUR$14,995USD£12,051GBP
- Report
- March 2019
- 62 Pages
Global
€9444EUR$10,000USD£8,037GBP
- Report
- March 2019
- 33 Pages
Global
€9444EUR$10,000USD£8,037GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €472EUR$500USD£402GBP
- Report
- January 2025
- 90 Pages
Global
From €3500EUR$3,970USD£3,083GBP

Abilify is a medication used to treat mental disorders such as schizophrenia, bipolar disorder, and major depressive disorder. It is an atypical antipsychotic drug, meaning it works differently than traditional antipsychotics. Abilify works by blocking certain receptors in the brain, which helps to reduce symptoms of mental illness. It is available in both oral and injectable forms.
Abilify is one of the most widely prescribed medications for mental disorders, and is used by millions of people around the world. It is generally well-tolerated and has few side effects. It is also one of the most expensive medications on the market, and is often not covered by insurance.
Some of the companies in the Abilify market include Otsuka Pharmaceuticals, Bristol-Myers Squibb, and Lundbeck. Show Less Read more